NASDAQ:ARDM - Aradigm Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.18 -0.01 (-5.26 %) (As of 03/20/2019 04:00 PM ET)Previous Close$0.19Today's Range$0.18 - $0.2152-Week Range$0.0701 - $2.33Volume985 shsAverage Volume97,091 shsMarket Capitalization$2.74 millionP/E Ratio-0.25Dividend YieldN/ABeta1.57 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California. Receive ARDM News and Ratings via Email Sign-up to receive the latest news and ratings for ARDM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARDM Previous Symbol CUSIPN/A CIK1013238 Webwww.aradigm.com Phone510-265-9000Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.23Price-To-Earnings Trailing P/E Ratio-0.25 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$14.47 million Price / Sales0.19 Cash FlowN/A Price / Cash FlowN/A Book Value($0.83) per share Price / Book-0.22Profitability EPS (Most Recent Fiscal Year)($0.72) Net Income$-10,700,000.00 Net Margins-374.80% Return on EquityN/A Return on Assets-374.15%Miscellaneous EmployeesN/A Outstanding Shares15,220,000Market Cap$2.74 million Next Earnings Date3/22/2019 (Estimated) OptionableOptionable Aradigm (NASDAQ:ARDM) Frequently Asked Questions What is Aradigm's stock symbol? Aradigm trades on the NASDAQ under the ticker symbol "ARDM." How were Aradigm's earnings last quarter? Aradigm Co. (NASDAQ:ARDM) announced its earnings results on Thursday, November, 15th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.03. The business earned $0.28 million during the quarter. View Aradigm's Earnings History. When is Aradigm's next earnings date? Aradigm is scheduled to release their next quarterly earnings announcement on Friday, March 22nd 2019. View Earnings Estimates for Aradigm. Has Aradigm been receiving favorable news coverage? News articles about ARDM stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aradigm earned a coverage optimism score of 1.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the near term. Who are some of Aradigm's key competitors? Some companies that are related to Aradigm include Nexeon Medsystems (NXNN), Vaso (VASO), Non-Invasive Monitoring Systems (NIMU), Reshape Lifesciences (RSLS), CHF Solutions (CHFS), Magna-Lab (MAGAA), Trimedyne (TMED), Escalon Medical (ESMC), Guided Therapeutics (GTHP), Fc Global Realty (FCRE), Newcardio (NWCI), Echo Therapeutics (ECTE), IMRIS (IMRSQ), 21st North (ULGX) and Nexeon Medsystems (NXNND). What other stocks do shareholders of Aradigm own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aradigm investors own include Synergy Pharmaceuticals (SGYP), Helios and Matheson Analytics (HMNY), MannKind (MNKD), Curis (CRIS), AcelRx Pharmaceuticals (ACRX), Celldex Therapeutics (CLDX), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX), Agenus (AGEN) and Vical (VICL). Who are Aradigm's key executives? Aradigm's management team includes the folowing people: Dr. John M. Siebert, Exec. Chairman, Interim Principal Exec. Officer & Acting Principal Financial Officer (Age 79)Dr. Juergen Froehlich M.D., MBA, FCPh, Chief Medical Officer (Age 62)Dr. Igor Gonda, Consultant (Age 71)Ms. Nancy E. Pecota, Consultant (Age 59)Lisa Thomas, Corp. Controller How do I buy shares of Aradigm? Shares of ARDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aradigm's stock price today? One share of ARDM stock can currently be purchased for approximately $0.18. How big of a company is Aradigm? Aradigm has a market capitalization of $2.74 million and generates $14.47 million in revenue each year. The company earns $-10,700,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. What is Aradigm's official website? The official website for Aradigm is http://www.aradigm.com. How can I contact Aradigm? Aradigm's mailing address is 3929 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-265-9000 or via email at [email protected] MarketBeat Community Rating for Aradigm (NASDAQ ARDM)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 159 (Vote Outperform)Underperform Votes: 226 (Vote Underperform)Total Votes: 385MarketBeat's community ratings are surveys of what our community members think about Aradigm and other stocks. Vote "Outperform" if you believe ARDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/20/2019 by MarketBeat.com StaffFeatured Article: What are gap-up stocks?